🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Characterization of Acute and Recent HIV-1 Infections in Zurich.

Recruitingn/aAges 18 Years - anyAllUniversity of Zurich
NCT00537966 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Aim of the study: To study and to describe factors which could influence the course of primary HIV infection (PHI) and factors that in turn could be influenced through PHI. In summary, this study will provide comprehensive knowledge on early HIV-infection with regard to epidemiology, impact of early-cART on the course of disease and forms the base for a variety of translational research projects addressing early key pathogenesis events between virus and host, relevant for the course of disease, for transmission, for development of vaccines and new treatment strategies.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: A) acute HIV-1 infection, defined as: * negative or evolving immunoblot in the presence of positive p24 Ag and/or detectable plasma HIV-1 RNA and/or * documented HIV seroconversion within 90 dayswith or with-out symptoms and/or clinical signs of PHI (e.g. acute retro-viral syndrome). B) recent HIV-1 infection, defined as: * documented seroconversion of more than 90 days but within 180 days and/or * evolving immunoblot after unambiguous transmission risk (e.g. iv drug use, sexual contact) within 180 days and/or * documented HIV infection and unambiguous transmission risk (iv drug use, sexual contact) within 180 days and/or * documented HIV infection and possible transmission risk (iv drug use, sexual contact) within the last 180 days after infection AND \< 0.5% fraction of ambiguous nucleotides Exclusion Criteria: • Documented HIV infection, however, established diagnosis more than 180 days after presumed date of infection.
💊

What it tests

  • Not listed
📍

Where

1 site
University of Zurich
Zurich, Switzerland
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy